In a report released today, Sarah James from Cantor Fitzgerald reiterated a Buy rating on HCA Healthcare, with a price target of $444.00. The company’s shares opened today at $435.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, James is a 4-star analyst with an average return of 6.1% and a 58.16% success rate. James covers the Healthcare sector, focusing on stocks such as Tenet Healthcare, Centene, and HCA Healthcare.
Currently, the analyst consensus on HCA Healthcare is a Moderate Buy with an average price target of $408.69.
Based on HCA Healthcare’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $18.61 billion and a net profit of $1.65 billion. In comparison, last year the company earned a revenue of $17.49 billion and had a net profit of $1.46 billion
Read More on HCA:
Disclaimer & DisclosureReport an Issue
- HCA Healthcare price target raised to $412 from $375 at Wells Fargo
- Nutex Health appoints Wesley Bamburg as COO
- HCA Healthcare price target raised to $445 from $390 at Barclays
- HCA Healthcare price target raised to $430 from $375 at BofA
- HCA Healthcare price target raised to $417 from $404 at Bernstein
/Advanced%20Micro%20Devices%20Inc_%20office%20sign-by%20Poetra_RH%20via%20Shutterstock.jpg)
/Alphabet%20(Google)%20Image%20by%20Markus%20Mainka%20via%20Shutterstock.jpg)
/An%20image%20of%20a%20Tesla%20humanoid%20robot%20in%20front%20of%20the%20company%20logo%20Around%20the%20World%20Photos%20via%20Shutterstock.jpg)